Desiree Ratner

Guest Editor for the following articles:

Vol. 30. No. 1

Merkel Cell Carcinoma: Update and Review

Janis M. Taube, MD | Lisa K. Jacobs, MD | Patrick J. Byrne, MD, FACS | Timothy S. Wang, MD

Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal cutaneous malignancy
that is not usually suspected at the time of biopsy. Because of its increasing incidence and
the discovery of a possible viral association, interest in MCC has escalated. Recent effort
has broadened our breadth of knowledge regarding MCC and developed instruments to
improve data collection and future study. This article provides an update on current thinking
about the Merkel cell and MCC.
Semin Cutan Med Surg 30:48-56 © 2011 Elsevier Inc. All rights reserved.

Vol. 30. No. 1

The Role of Targeted Molecular Inhibitors in the Management of Advanced Nonmelanoma Skin Cancer

Desiree Ratner, MD | Kevin W. O\’Bryan, MD

Surgical treatment remains the standard of care for nonmelanoma skin cancer and is
successful for the vast majority of patients with these tumors. The treatment of patients
with metastatic or unresectable nonmelanoma skin cancer, however, has until recently
been based solely on traditional methods of chemotherapy and radiation. However, these
methods have high rates of treatment failure, morbidity, and mortality, and alternative
treatment modalities for patients with aggressive or advanced disease are needed. As in
other areas of cancer therapeutics, recent research elucidating the molecular basis of
cancer development, and the subsequent arrival of targeted molecular inhibitors for cancer
therapy, have been met with much excitement. In this review, we seek to illuminate recent
developments and future possibilities in the use of targeted molecular inhibitors for
treatment of advanced squamous cell carcinoma, basal cell carcinoma, and dermatofibrosarcoma
Semin Cutan Med Surg 30:57-61 © 2011 Published by Elsevier Inc.